Results 51 to 60 of about 2,543,810 (186)

Kounis syndrome secondary to amoxicillin/clavulanic acid use

open access: yes, 2008
Myocardial injury and acute coronary syndrome have been rarely associated with amoxicillin/clavulanic acid intake. The responsible pathogenetic mechanism is described by an amplified mast cell degranulation inducing coronary artery spasm and/or acute ...
TÜRKOĞLU, SEDAT   +3 more
core   +1 more source

Idiosyncratic hepatic toxicity in autosomal dominant polycystic kidney disease (ADPKD) patient in combined treatment with tolvaptan and amoxicillin/clavulanic acid: a case report

open access: yesBMC Nephrology, 2019
Background Autosomal dominant polycystic kidney disease (ADPKD) is a hereditary disease characterized by the presence of renal cysts. Over time the expanding cysts lead to progressive renal failure.
Angela Maria Pellegrino   +3 more
doaj   +1 more source

Amoxycillin-clavulanic acid treatment of melioidosis.

open access: yes, 1991
Melioidosis is a serious infection with high acute mortality, and a high rate of relapse despite protracted antimicrobial treatment. The current recommended conventional oral treatment regimen is a 4-drug combination of high-dose chloramphenicol ...
Dance, DA   +6 more
core   +1 more source

Human pharmacokinetics and CSF penetration of clavulanic acid [PDF]

open access: yes, 2017
Clavulanic acid, a product of Streptomyces clavuligerus with β-lactam structure, is a potent inhibitor of several β-lactamases. To study its pharmacokinetic and CSF penetration in patients without meningeal inflammation, a single oral dose of 250 mg of ...
Blaser, J.   +3 more
core  

Exploring the activity of a novel orally bioavailable β-lactam-β-lactamase inhibitor combination, ceftibuten-ledaborbactam, against Enterobacterales-carrying blaOXA-48

open access: yesMicrobiology Spectrum
Ledaborbactam is a novel boronic-acid inhibitor of class A, C, and D β-lactamases, including OXA-48, being developed in combination with ceftibuten. Herein, we examined the in vitro activity of this combination vs.
Maria F. Mojica   +6 more
doaj   +1 more source

Evaluation of Amoxicillin-Clavulanic Acid Bismuth Combination for Helicobacter Pylori Eradication [PDF]

open access: yesAfro-Egyptian Journal of Infectious and Endemic Diseases
Background and study aim:   The prevalence of Helicobacter pylori (H. pylori) infection in Egypt is considered high, and its treatment is challenging due to high levels of antibiotic resistance.
Abdelmonem Elshamy   +8 more
doaj   +1 more source

Extraction of clavulanic acid using aqueous two-phase micellar system

open access: yes, 2011
An investigation of clavulanic acid behavior in an aqueous two-phase micellar system employing the surfactants n-decyltetraethylene oxide (C(10)E(4)) and dodecyldimethylamine oxide (DDAO) was carried out.
Evelyn Guedes de Andrade   +11 more
core   +1 more source

Actinomycetoma treated with trimethoprim/sulfamethoxazole and amoxicillin/clavulanic acid.

open access: yes, 2020
(A) Two-year-old Nocardia brasiliensis mycetoma on the right sole. (B) Complete resolution after 7 months of treatment with trimethoprim/sulfamethoxazole and amoxicillin/clavulanic acid.
Luis Gerardo Cruz-Gómez (8544732)   +8 more
core   +1 more source

Antimicrobial Susceptibility of Stenotrophomonas maltophilia Clinical Isolates from Blood Samples in Iran

open access: yesJournal of Medical Microbiology and Infectious Diseases, 2015
Introduction: Stenotrophomonas maltophilia is a nosocomial multi drug resistant opportunistic pathogen which causes infections in vulnerable patients with cancer, cystic fibrosis and indwelling catheters. Methods: 45 clinical S. maltophilia isolates were
Amir Hesam Nemati   +3 more
doaj  

Bibliometric Analysis of Global Research on Clavulanic Acid

open access: yesAntibiotics, 2018
Clavulanic acid (CA), a potent inhibitor of the β-lactam, ase enzyme, is frequently co-formulated with a broad spectrum of antibiotics to treat infections caused by β-lactamase-producing pathogens.
Howard Ramirez-Malule
doaj   +1 more source

Home - About - Disclaimer - Privacy